Biotech and Pharmaceuticals Pharmaceuticals

  • Accelerating Ebola vaccine

    CNBC's Meg Tirrell speaks to Johnson & Johnson chairman, Joaquin Duato, about J&J's partnership with the National Institutes of Health to fast track its Ebola vaccine program to begin human testing by early 2015.

  • CNBC's Andrea Day reports on a former convicted drug smuggler who has turned to selling diet supplements.

  • Infinity Pharma teams up with AbbVie for cancer drug

    Infinity Pharma will receive $275 million upfront from AbbVie, as part of a new venture to develop blood cancer treatments. Infinity CEO Adelene Q. Perkins, explains the significance of the deal, with CNBC's Meg Tirrell.

  • Biotech's $10 billion opportunity

    CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.

  • Kite Pharma's positive cancer drug study results

    Kite Pharma is working on a treatment which involves taking a cancer patient's own t-cells out of their body, genetically modifying them to better target cancer, and then re-administering them. Its CEO Arie Belldegrun, provides insight to the positive study with the therapy.

  • A pharmacist searches for drugs in a pharmacy in Lagos, Nigeria, July, 2014.

    Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.

  • Roche's blockbuster pharma deal

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • Roche CEO: InterMune perfect strategic fit

    CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.

  • 'Surprised' at value of Roche-Intermune deal: Pro

    Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.

  • The first British citizen confirmed to be infected with the deadly Ebola disease is being evacuated from Sierra Leone.

  • Big change for pain drugs

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Fighting obesity with Rxs

    Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.

  • Next wave of diet drugs

    Obesity has big potential for drug makers. CNBC's Meg Tirrell examines why physicians have been cautious to adopt new diet drugs.

  • Obesity treatment sales fall short

    CNBC's Meg Tirrell provides insight to the definition of obesity by the CDC, and which drug companies are working on treatments in the space.

  • Women washing along the Niger River near Babila, Guinea.

    Ebola outbreaks may become more frequent because of climate change, scientists warn, as the deadly disease ravages West Africa.

  • Amgen's cancer drug fails to improve survival rates

    Yaron Werber, Citi Investment Research, shares his thoughts on news Kyprolis failed to meet its primary endpoint of improving overall survival for patients with multiple myeloma.

  • Investors should expect more from Merck: Pro

    Raghuram Selvaraju, head of healthcare equity research at Aegis Capital, says "German Merck's" second quarter was "solid and respectable" but that its biopharmaceutical business is its weak spot.

  • Cramer's Mad Dash: Intercept soars

    Jim Cramer explains what to watch ahead of the open, including Intercept Pharmaceuticals.

  • A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to GlaxoSmithKline.

  • A man purchases medical marijuana, the first legal sale, at Capital City Care in Washington, DC. The District of Columbia city council is to vote on decriminalizing pot.

    U.S. scientists face legal obstacles and frustrations in trying to study the medical uses of marijuana, the New York Times reports.